Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2279420 | 0.84 | DGAT1 (0.38) | DGAT1CA12CA2CA14PTPRC | |
| SCHEMBL2282604 | 0.76 | DGAT1 (0.45) | DGAT1CA12CA2CA14TDP1 | |
| SCHEMBL756932 | 0.76 | CA2 (0.39) | DGAT1CA12CA2CA14TDP1 | |
| SCHEMBL2280101 | 0.73 | DGAT1 (0.42) | DGAT1CA12CA2CA14TDP1 | |
| SCHEMBL7428244 | 0.73 | DGAT1 (0.47) | DGAT1CA12CA2CA14TDP1 | |
| SCHEMBL21564883 | 0.71 | CA2 (0.36) | DGAT1CA12CA2CA14TDP1 | |
| SCHEMBL23894059 | 0.71 | CA2 (0.41) | DGAT1CA12CA2CA14TDP1 | |
| SCHEMBL783009 | 0.71 | CA2 (0.41) | DGAT1CA12CA2CA14TDP1 | |
| SCHEMBL21625398 | 0.70 | DGAT1 (0.36) | DGAT1CA12CA2CA14PTPRC | |
| SCHEMBL6097359 | 0.69 | CA2 (0.35) | DGAT1CA12CA2CA14TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989649-B2 | Tumor imaging compounds | EMORY UNIVERSITY (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1499584-B1 | TUMOR IMAGING COMPOUNDS | UNIV EMORY (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090240041-A1 | TUMOR IMAGING COMPOUNDS | EMORY UNIVERSITY (US) | 2009-09-24 | — | — | US | disclosed |
| US-7544715-B2 | Tumor imaging compounds | EMORY UNIVERSITY (US) | 2009-06-09 | — | — | US | disclosed |
| EP-1499584-A4 | TUMOR IMAGING COMPOUNDS | UNIV EMORY (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20050192458-A1 | radiolabeled amino acids for use as metabolic tracers to image tumors using positron emission tomography; combine the advantageous properties of alpha -aminoisobutyric acid analogs namely, their rapid uptake and prolonged retention in tumors with the properties of halogen sustituents | EMORY UNIVERSITY | 2005-09-01 | — | — | US | disclosed |
| EP-1499584-A2 | TUMOR IMAGING COMPOUNDS | Emory University (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003093412-A2 | TUMOR IMAGING COMPOUNDS | EMORY UNIVERSITY (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192458-A1 | radiolabeled amino acids for use as metabolic tracers to image tumors using positron emission tomography; combine the advantageous properties of alpha -aminoisobutyric acid analogs namely, their rapid uptake and prolonged retention in tumors with the properties of halogen sustituents | SLC43A1, SLC1A5, SSTR4 | DGAT1 4150/4885CA12 126/4885CA2 993/4885 |
| US-20090240041-A1 | TUMOR IMAGING COMPOUNDS | AADAT, MKI67, SSTR1 | DGAT1 4582/4885CA12 57/4885CA2 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.